PITTSBURGH, Nov. 7, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq:
MYL) today announced it has signed a multi-year strategic alliance
agreement with Walt Disney Parks and
Resorts to help increase awareness of anaphylaxis, a
life-threatening (severe) allergic reaction. The agreement includes
updated maps in Disney's domestic theme parks and on its cruise
ships as well as updated signage in the parks that highlight
locations with EpiPen® (epinephrine) and EpiPen
Jr® (epinephrine) Auto-Injectors. Over time, the
companies also will introduce a variety of educational resources
designed to increase awareness of and preparedness for severe
allergic reactions.
EpiPen® locations will roll out at Disney parks and
on cruise ships beginning in late 2014. In addition to emergency
medical services (EMS), nurses trained to administer EpiPen
Auto-Injectors are available during First Aid station operating
hours to assist guests experiencing a severe allergic reaction. To
help guests identify EpiPen locations, Disney's guide maps
will now include an EpiPen Auto-Injector symbol and new
signage at First Aid stations.
"Mylan's mission is to provide the world's 7 billion people
access to high quality medicine and set new standards in health
care. In support of this mission, we are committed to enhancing
access to EpiPen Auto-Injectors and to increasing awareness
of anaphylaxis. Like life, severe allergic reactions are
unpredictable, so people need to be prepared," said Mylan CEO
Heather Bresch. "We are very proud
to be working with Disney, which already has a strong reputation
for meeting the needs of people managing severe allergies, and
believe we can further raise awareness of anaphylaxis through this
collaboration and our joint commitment to education."
Anaphylaxis is unpredictable, and can progress quickly and
without warning. Clinical guidelines state that epinephrine is the
first-line treatment when anaphylaxis occurs, making access
critical. For those with a known risk, it is important to be
prepared with an anaphylaxis action plan that includes 1) avoiding
known allergens, 2) recognizing the signs and symptoms of
anaphylaxis, 3) having immediate access to two epinephrine
auto-injectors, such as EpiPen Auto-Injector, and 4) seeking
immediate emergency medical care should anaphylaxis occur.
"For our guests who live with severe allergies every day,
identifying EpiPen locations is an additional tool they'll
have for their anaphylaxis management plan," said Dr. Pamela Hymel, chief medical officer for
Walt Disney Parks and Resorts. "This
new strategic alliance will help raise awareness of EpiPen
locations so that our Guests with severe allergies may have the
best possible experience at our parks and on our cruise ships."
Families managing known severe allergies are encouraged to
follow their individual anaphylaxis action plans and carry their
epinephrine auto-injectors with them at all times.
Indications
EpiPen® (epinephrine) 0.3 mg
and EpiPen Jr® (epinephrine) 0.15 mg Auto-Injectors are
for the emergency treatment of life-threatening allergic reactions
(anaphylaxis) caused by allergens, exercise, or unknown triggers;
and for people who are determined to be at increased risk for these
reactions. EpiPen and EpiPen Jr are intended for
immediate self administration as emergency supportive therapy only.
Seek immediate emergency medical treatment after use.
Important Safety Information
EpiPen
Auto-Injectors contain a single dose of epinephrine, which you
inject into your outer thigh. DO NOT INJECT INTO YOUR VEIN,
BUTTOCK, FINGERS, TOES, HANDS OR FEET. In case of accidental
injection, please seek immediate medical treatment. Epinephrine
should be used with caution if you have heart disease or are taking
certain medicines that can cause heart-related (cardiac)
symptoms.
Tell your doctor if you have certain medical conditions such as
asthma, depression, thyroid disease, Parkinson's disease, diabetes,
high blood pressure and heart disease, have any other medical
conditions, are pregnant or plan to become pregnant, or are
breastfeeding or plan to breastfeed. Be sure to also tell your
doctor all the medicines you take, especially medicines for asthma.
If you have certain medical conditions, or take certain
medicines, your condition may get worse or you may have longer
lasting side effects when you take the EpiPen or EpiPen
Jr Auto-Injector.
The most common side effects may include increase in heart rate,
stronger or irregular heartbeat, sweating, nausea and vomiting,
difficulty breathing, paleness, dizziness, weakness or shakiness,
headache, apprehension, nervousness or anxiety. These side effects
usually go away quickly, especially if you rest.
Talk to your healthcare professional to see if EpiPen or
EpiPen Jr Auto-Injector is right for you.
Please see the full Prescribing Information and Patient
Information.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or
call 1-800-FDA-1088.
About EpiPen® (epinephrine)
Auto-Injector
EpiPen® (epinephrine) and EpiPen
Jr® (epinephrine) Auto-Injectors are used for the
emergency treatment of life-threatening allergic reactions. Each
EpiPen 2-Pak® and EpiPen Jr 2-Pak® contains
two single auto-injectors, instructions for use and a training
device, with no drug product or needle, to help patients become
familiar with the administration technique. EpiPen
Auto-Injector should be administered immediately at the first
sign of an anaphylactic reaction. EpiPen Auto-Injector is
not a substitute for emergency medical treatment. Patients should
seek emergency medical attention immediately following
administration. EpiPen Auto-Injector has been the No. 1
prescribed epinephrine auto-injector for more than 25 years and has
three-step simple instructions for use. For more information about
EpiPen Auto-Injector, please visit www.EpiPen.com.
About Mylan
Mylan is a global pharmaceutical company
committed to setting new standards in health care. Working together
around the world to provide 7 billion people access to high quality
medicine, we innovate to satisfy unmet needs; make reliability and
service excellence a habit; do what's right, not what's easy; and
impact the future through passionate global leadership. We offer a
growing portfolio of more than 1,300 generic pharmaceuticals and
several brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. Learn more at mylan.com
About Walt Disney Parks and
Resorts
More than 50 years ago, Walt
Disney created a new kind of entertainment families could
experience together, immersed in detailed atmospheres and vibrant
storytelling. His vision now includes a collection of five of the
world's leading family vacation destinations – Disneyland Resort,
Anaheim, Calif.; Walt Disney World
Resort, Lake Buena Vista, Fla.;
Tokyo Disney Resort, Urayasu,
Chiba, Japan; Disneyland Paris,
Marne-la-Vallee, France; and Hong
Kong Disneyland Resort, located on Lantau Island. A sixth resort,
Shanghai Disney Resort, is currently under construction in Pudong
New District, Shanghai. In
addition, Walt Disney Parks and
Resorts includes the world-class Disney Cruise Line; Disney
Vacation Club; Adventures by Disney, a guided group vacation
experience to some of the world's most popular destinations; and
Walt Disney Imagineering, which creates and designs all Disney
parks, resorts, cruise ships, entertainment and attractions.
EpiPen®, EpiPen Jr®, EpiPen
2-Pak® and EpiPen Jr 2-Pak® are registered
trademarks of Mylan Inc. licensed exclusively to its wholly-owned
subsidiary, Mylan Specialty L.P.
SOURCE Mylan Inc. and The Walt Disney Company
EPI-2014-1099
Logo - http://photos.prnewswire.com/prnh/20140423/77793
PDF -
http://origin-qps.onstreammedia.com/origin/multivu_archive/ENR/Disneys-Hollywood-Studios-Guidemap-Asset.pdf
SOURCE Mylan Inc.